E in pregnant patients with connective tissue diseases. Review of the
E in pregnant patients with connective tissue diseases. Review of the literature. Autoimmun Rev. 2005;4:111?. 83. Ojeda-Uribe M, Afif N, Dahan E, Sparsa L, Haby C, Sibilia J, et al. Exposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases. Clin Rheumatol. 2013;32:695?00. 84. Hyrich KL, Verstappen SM. Biologic therapies and pregnancy: the story so far. Rheumatology PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/25447644 (Oxford). 2014;53:1377?5. 85. Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011;117:1499?06. 86. Fischer-Betz R, Specker C, Schneider M. Successful outcome of two pregnancies in patients with adult-onset Still’s disease treated with IL-1 receptor antagonist (anakinra). Clin Exp Rheumatol. 2011;29:1021?. 87. Ostensen M, F ger F. Treatment with biologics of pregnant patients with rheumatic diseases. Curr Opin Rheumatol. 2011;23:293?. 88. Lu E, Wang BW, Guimond C, Synnes A, Sadovnick D, Tremlett H. Diseasemodifying drugs for multiple sclerosis in pregnancy: a systematic review. Neurology. 2012;79:1130?. 89. Ebrahimi N, Herbstritt S, Gold R, Amezcua L, Koren G, Hellwig K. Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study. Mult Scler. 2014;21:198?05. 90. Karlsson G, Francis G, Koren G, Heining P, Zhang X, Cohen JA, et al. Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Neurology. 2014;82:674?0. 91. Soleimani R, Heytens E, Oktay K. Enhancement of neoangiogenesis and follicle survival by sphingosine-1-phosphate in human ovarian tissue xenotransplants. PLoS One. 2011;6:e19475. 92. Zelinski MB, Murphy MK, Lawson MS, Jurisicova A, Pau KY, Toscano NP, et al. In vivo delivery of FTY720 A-836339 chemical information prevents radiation-induced ovarian failure and infertility in adult female nonhuman primates. Fertil Steril. 2011;95:1440?. 93. Poels J, Abou-Ghannam G, Herman S, Van Langendonckt A, Wese FX, Wyns C. In Search of Better Spermatogonial Preservation by Supplementation of Cryopreserved Human Immature Testicular Tissue Xenografts with Nacetylcysteine and Testosterone. Front Surg. 2014;1:47. e collection 2014. 94. Su HI, Maas K, Sluss PM, Chang RJ, Hall JE, Joffe H. The impact of depot GnRH agonist on AMH levels in healthy reproductive-aged women. J Clin Endocrinol Metab. 2013;98:E1961?. 95. Del Mastro L, Ceppi M, Poggio F, Bighin C, Peccatori F, Demeestere I, et al. Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials. Cancer Treat Rev. 2014;40:675?3.
Veszeli et al. Orphanet Journal of Rare Diseases (2015) 10:156 DOI 10.1186/s13023-015-0374-yRESEARCHOpen AccessNeutrophil activation during attacks in patients with hereditary angioedema due to C1-inhibitor deficiencyN a Veszeli1, Dorottya Csuka1, Zsuzsanna Zotter1,2, a Imreh3, Mih y J si4, Szabolcs Benedek5, Lilian Varga1 and Henriette Farkas1*AbstractBackground: Earlier studies have shown that the absolute number of neutrophil granulocytes (NGs) may increase during attack of hereditary angioedema due to C1-inhibitor deficiency (C1-INH-HAE). Whether NGs undergo activation during attack has not yet been investigated. However, as neutrophil elastase (NE) can cleave and inactivate C1-INH which may contribute to the dysregulation of the kallikrein-kinin system and hence, to edema formation. Our PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/28242652 aim was to inv.